I think if data is good bp will want in. They can't wait till phase 3 as there will be huge competition if this is in fact working. They would want to be apart of the phase 3 trial. A buyout after trial if work would be huge $$$. We have had so many failure in Alzhiemers maybe this is the one they are looking at it differently.